ATHE · Alterity Therapeutics Ltd · Insider Trading
Market Cap
$73.74M
Shares
18.21M
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
81
Net buyers
+1
Net shares bought
0.26%
Net buy value
+$23,810
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-31 | Marks Peter Ashley |
Director |
Buy↑
|
Ordinary shares
(I)
|
47,620 |
| 2026-08-31 | Marks Peter Ashley |
Director |
Buy↓
|
Listed option exp 31 Aug 2026
(I)
|
47,620 |
| 2026-08-31 | Stamler David Allen |
Director, Chief Executive Officer |
Buy↓
|
Listed option exp 31 Aug 2026
|
47,620 |
| 2026-06-15 | Gozlan Lawrence Bernard |
Director |
Award↑
|
Listed option exp 15 Jun 2031
(I)
|
1,000,000 |
| 2026-06-15 | Babarczy Julian Michael |
Director |
Award↑
|
Unlisted option exp 15 Jun 2031
(I)
|
2,000,000 |
Legend
Buy — open-market purchase
Sell — open-market sale
↑ Shares acquired
↓ Shares disposed (gift, conversion, tax…)
Showing 1–5 of 5 transactions